Alzamend Neuro is trading at $1.62, down 6.36%, with no clear cause for the decline identified in available evidence.
- No company-specific announcement dated October 1 appeared on the press-release page; the latest release was September 16, about regaining Nasdaq listing compliance.
- The previously announced lithium-imaging presentation was scheduled for September 29 at an international workshop and does not establish a new October 1 catalyst.
- Major indexes were mixed, rather than moving sharply in the same direction as the stock.